Aortic regurgitation Medical Services in China

Aortic regurgitation (AR), also known as aortic insufficiency, is a valvular heart disease characterized by incomplete closure of the aortic valve, resulting in retrograde blood flow from the aorta into the left ventricle during diastole. This chronic volume overload leads to progressive left ventricular dilation and hypertrophy, ultimately impairing systolic function and increasing risk of heart failure, arrhythmias, and sudden cardiac death if untreated. Etiologies include degenerative valve disease, bicuspid aortic valve, infective endocarditis, aortic root dilation (e.g., Marfan syndrome or annuloaortic ectasia), and rheumatic heart disease. Diagnosis relies on echocardiography—particularly transthoracic and transesophageal Doppler—to quantify regurgitant fraction, effective regurgitant orifice area, and left ventricular dimensions and ejection fraction. Indications for intervention include symptomatic severe AR, asymptomatic severe AR with LV dysfunction (EF <50%) or progressive LV dilation (end-systolic dimension >50 mm), or planned non-cardiac surgery in patients with severe AR.

China offers distinct advantages for international patients seeking definitive treatment—primarily surgical aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI) in select cases. Leading cardiovascular centers, such as Fu Wai Hospital and Shanghai Ruijin Hospital, combine decades of expertise in complex valve surgery with state-of-the-art imaging (3D TEE, 4D flow MRI), robotic-assisted minimally invasive techniques, and high-volume experience—over 10,000 AVR procedures annually across top-tier institutions. Clinical outcomes align with international benchmarks: 30-day mortality for isolated AVR remains below 2.5%, and 5-year survival exceeds 85% in appropriately selected patients. Crucially, costs are typically 40–60% lower than in the US or Western Europe without compromising quality—comprehensive packages including preoperative evaluation, surgery, ICU care, and rehabilitation start at USD 25,000–35,000. As a dedicated medical tourism agency, we facilitate seamless access: coordinating appointments with nationally certified cardiac surgeons, verifying hospital accreditation and surgeon credentials, providing itemized, transparent pricing, arranging visas and local logistics, and offering multilingual clinical support throughout the care journey—from initial consultation to post-discharge follow-up.

Treatment Options & Itemized Cost Breakdown: Aortic Regurgitation (Cardiovascular Department)

I. Non-Surgical / Conservative Management

*Indicated for asymptomatic mild-to-moderate AR, preserved LVEF (>50%), and stable LV size (LVEDD <65 mm).*

• •Medications:

- Beta-blockers (e.g., bisoprolol): $8–$22/month - Diuretics (e.g., furosemide) if volume overload: $4–$15/month

• •Monitoring:

- BNP/NT-proBNP assay: $24–$42 - Annual Holter + exercise stress test: $95–$160 - Routine labs (renal function, electrolytes, CBC): $32–$58

II. Surgical & Interventional Options

*Eligibility: Symptomatic severe AR, LVEF ≤50%, LVEDD ≥65 mm, or progressive LV dilation despite medical therapy.*

• •Surgical Aortic Valve Replacement (SAVR):

- Bioprosthetic valve (e.g., Edwards Perimount): $10,800–$14,300

• •Transcatheter Aortic Valve Replacement (TAVR):

- Self-expanding (e.g., Medtronic Evolut PRO+): $18,900–$23,700

• •Preoperative Workup (mandatory):

- CT aortography (valve sizing + access assessment): $1,050–$1,630 - Pulmonary function test + carotid duplex: $380–$620

III. Special/Complex Scenarios

• •AR with ascending aorta >50 mm or rapid dilation (>3 mm/year): Combined aortic root replacement (Bentall procedure): $15,400–$19,800
• •Active endocarditis with valve destruction: Urgent SAVR + prolonged IV antibiotics (4–6 weeks): $12,900–$17,200 (includes ICU stay, blood cultures, TEE)
• •Renal failure (eGFR <30 mL/min): TAVR preferred; dialysis coordination adds $1,800–$2,600

IV. Quick Selection Guide

• •<65 years, no comorbidities, high activity demand: Mechanical SAVR — durable, cost-effective long-term ($8,200), lifelong anticoagulation required.
• •≥75 years, frailty/comorbidities (COPD, CKD): TAVR — lower perioperative risk, faster recovery ($17,600–$23,700); avoids sternotomy.
• •Moderate AR, age 50–70, borderline LV dilation: Conservative + strict 6-month echo surveillance — total annual cost $1,400–$2,300, defers intervention.
• •Severe AR + Marfan syndrome or bicuspid aorta: SAVR + ascending aorta replacement — prevents dissection; upfront cost $15,400–$19,800, essential for survival.
• •Low-income patients (<$3,000/year): ACEi/ARB + biannual echo ($110–$185) — delays surgery while maintaining stability; government subsidy may cover up to 70% of SAVR in public hospitals.